Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-Reduced [busulfan + fludarabine] Versus Standard Conditioning [busulfan + cyclophosphamide] Followed by Allogeneic Stem Cell Transplantation in Patients With MDS [myelodysplastic syndromes] or sAML [secondary acute myeloid leukaemia]: A Randomised Phase III Study (RICMAC)

Next Previous
Trial Profile

Dose-Reduced [busulfan + fludarabine] Versus Standard Conditioning [busulfan + cyclophosphamide] Followed by Allogeneic Stem Cell Transplantation in Patients With MDS [myelodysplastic syndromes] or sAML [secondary acute myeloid leukaemia]: A Randomised Phase III Study (RICMAC)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Busulfan; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms RICMAC

Most Recent Events

  • 04 Dec 2018 Long-term follow up results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 02 May 2017 Results published in the Journal of Clinical Oncology
  • 02 Apr 2015 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top